

CITATION REPORT

List of articles citing

Cost-effectiveness of
Ombitasvir/Paritaprevir/Ritonavir,
Dasabuvir+Ribavirin for US Post-Liver Transplant
Recurrent Genotype 1 HCV

DOI: 10.1111/liv.13033
Liver International, 2016, 36, 515-21.

Source: <https://exaly.com/paper-pdf/63448246/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. <i>MDM Policy and Practice</i> , 2016 , 1,	1.5	6
8	Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. <i>Transplantation</i> , 2017 , 101, 933-937	1.8	13
7	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. <i>Transplantation</i> , 2017 , 101, 987-995	1.8	16
6	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir + dasabuvir + ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 226-237	3.4	17
5	Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature review. <i>Antiviral Therapy</i> , 2019 , 24, 247-259	1.6	4
4	Elimination of Hepatitis C in Liver Transplant Recipients. <i>Journal of Clinical and Translational Hepatology</i> , 2018 , 6, 247-250	5.2	4
3	Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 101-108	5.2	8
2	Special Poster Feature: American Association for the Study of Liver Diseases (AASLD): The Liver Meeting + 2016 Coverage.		0
1	Viral proteases as therapeutic targets. 2022 , 88, 101159		1